PMID: 7543029Jan 1, 1995Paper

Prolonged daily administration of oral etoposide in lymphoma following prior therapy with adriamycin, an ifosfamide-containing salvage combination, and intravenous etoposide

Cancer Chemotherapy and Pharmacology
N HaimR Epelbaum

Abstract

Prolonged daily administration of oral etoposide has been reported to be active in refractory lymphoma. The purpose of this phase II trial was to confirm the activity of this schedule of etoposide in a selected group of heavily pretreated patients with non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD). A total of 26 patients (20 with NHL and 6 with HD) were entered in the trial; all had previously been treated with an Adriamycin-based chemotherapy, an ifosfamide-containing salvage combination, and i.v. etoposide. Etoposide was given in a fixed oral daily dose of 100 mg over 3 weeks; the weekly dose (500-700 mg) was selected such that the average daily dose was approximately 50 mg/m2. Cycles were repeated on day 29. An objective response was seen in 16 patients (62%; 95% confidence interval, 42%-80%), with a complete response (CR) being observed in 3 cases (12%) and a partial response (PR), in 13 (50%). The median duration of PRs was 3 months. CRs lasted for 15 months in one patient and continue at 12+ and 20+ months in the remaining two patients. The overall actuarial survival for the entire group was 40% at 2 years; the median survival time was 12 months. The main toxicity was myelosuppression; WHO grade 3 or 4 leukopenia...Continue Reading

References

Jan 1, 1991·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F Cabanillas
Jan 1, 1990·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J D HainsworthF A Greco
Sep 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M L SlevinP F Wrigley
Mar 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J D HainsworthF A Greco
Jan 1, 1981·Cancer·A B MillerA Winkler
May 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M MartínJ García-Conde
Jan 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P J Hoskins, K D Swenerton

❮ Previous
Next ❯

Citations

Feb 22, 2000·American Journal of Clinical Oncology·E FenigA Sulkes
Jun 25, 2009·Expert Opinion on Investigational Drugs·David P SamuelMark W Kieran
Oct 15, 2013·British Journal of Haematology·Graham P CollinsKarl S Peggs

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.